Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 53Lymphoma, Mantle-Cell 31Lymphoma, Large B-Cell, Diffuse 17Lymphoma, Non-Hodgkin 14Lymphoma 11Leukemia, B-Cell 6Lymphoma, Follicular 5Lymphoma, B-Cell, Marginal Zone 5Lymphoma, B-Cell 5Leukemia 5Waldenstrom Macroglobulinemia 4Multiple Myeloma 3Recurrence 2Pancreatic Neoplasms 2Lymphoproliferative Disorders 2Lymphatic Diseases 2Leukemia, Prolymphocytic 2Hematologic Neoplasms 2Squamous Cell Carcinoma of Head and Neck 1Pyloric Stenosis, Hypertrophic 1Part1: Advanced B-cell Malignancies 1Ovarian Neoplasms 1Neuritis 1Neoplasms 1Neoplasm, Residual 1Leukemia, Hairy Cell 1Immunoproliferative Disorders 1Immune System Diseases 1Hodgkin Disease 1Hematologic Diseases 1

Interventions

Paclitaxel 326Carboplatin 318Bevacizumab 167Gemcitabine 106pembrolizumab 101liposomal doxorubicin 100Cyclophosphamide 96Topotecan 93Cisplatin 89olaparib 86niraparib 60Docetaxel 56Taxes 52Doxorubicin 50Drug Therapy 42fludarabine 40Filgrastim 39Nivolumab 37Etoposide 32Specimen Handling 31Magnetic Resonance Spectroscopy 29Immunoglobulin G 27Disulfides 27Peripheral Blood Stem Cell Transplantation 26Albumin-Bound Paclitaxel 25durvalumab 24aldesleukin 24Hyperthermic Intraperitoneal Chemotherapy 24Oxaliplatin 23Biopsy 21

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Ovarian Neoplasms × acalabrutinib × Clear all
NCT02537444 2019-09-25

Acalabrutinib (ACP-196) Alone and in Combination With Pembrolizumab in Ovarian Cancer (KEYNOTE191)

Acerta Pharma BV

Phase 2 Completed
78 enrolled 10 charts
Gynecologic

Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡